Action Potential Waveform Analysis in Human IPSC-Cardiomyocytes Enables Mechanistic Assessment of Multichannel Cardiac Effects
For programmes targeting pain and epilepsy, accurate measurement of KV7 ion channel gating behaviour is critical. Metrion assays provide reproducible, high-content data to support confident compound progression.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.
Action Potential Waveform Analysis in Human IPSC-Cardiomyocytes Enables Mechanistic Assessment of Multichannel Cardiac Effects
Cardiac toxicity remains the leading cause of new drug safety side-effects. Current preclinical cardiac safety assays rely on in vitro cell-based ion channel assays and ex vivo and in vivo animal models⁽¹⁾. These assays provide an indication of acute risk but they do not always predict the effect of chronic compound exposure, as recently seen with oncology drugs. Therefore, new assays are required to characterise chronic structural and functional effects in human cells earlier in drug discovery. Impedance-based technology can provide more accurate chronic cardiotoxicity measurements in an efficient manner using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).